The above mentioned data in vitro and in vivo all indicated that COX-2 siRNA could silence expression of the COX-2 gene in Capan-2 cells and influence cell proliferation, cell cycle, cell apoptosis and tumorigenicity of Capan-2 cells, which may supply gene therapy of pancreatic cancer in clinical practice with therapeutic target and theoretical evidence. The gene discussed is PTGS2; the disease is familial pancreatic carcinoma.